Frequently Asked Questions:
- What is the STAR trial?
STAR is a phase 4, randomized, double-blind, placebo-controlled trial of guselkumab in 411 biologic-naive adults with active psoriatic arthritis and axial involvement confirmed by MRI.
- Did guselkumab reduce sacroiliac joint inflammation?
Yes. SPARCC MRI scores fell by 7.1 points with dosing every 4 weeks and 5.2 points with dosing every 8 weeks, compared with 2.4 points with placebo, at week 24.
- Is guselkumab approved for every-4-week dosing in psoriatic arthritis?
No. The every-4-week regimen evaluated in STAR is not approved in the US.
Guselkumab (Tremfya) significantly improved axial symptoms and reduced MRI-detected sacroiliac joint inflammation versus placebo in biologic-naive adults with active psoriatic arthritis (PsA) and axial involvement. Johnson & Johnson shared the late-breaking phase 4 STAR results at the 2026 Emirates Society for Rheumatology Annual Meeting.¹
There has been little prospective evidence specific to axial psoriatic arthritis, in part because no validated classification criteria exist for this disease domain. Johnson & Johnson described STAR as the first randomized, double-blind, placebo-controlled trial designed to prospectively study an interleukin-23 (IL-23) inhibitor in patients with MRI-confirmed axial involvement.¹,²
What Did the STAR Trial Show for Guselkumab in Axial Psoriatic Athritis?
STAR (NCT04929210) enrolled 411 participants worldwide with active psoriatic arthritis, axial inflammation confirmed by centrally read MRI, and elevated C-reactive protein (CRP). All had active disease despite prior treatment with non-biologic disease-modifying antirheumatic drugs, apremilast, or nonsteroidal anti-inflammatory drugs.² Those assessed were randomized to guselkumab 100 mg every 4 weeks (Q4W), guselkumab every 8 weeks (Q8W), or placebo for 24 weeks. All participants then received open active therapy for another 24 weeks.¹
The trial was shown to have met its primary endpoint, change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at week 24. On the 0-to-10 scale, mean BASDAI scores fell by 3.3 points with Q4W dosing and 2.9 points with Q8W dosing, compared with 2.1 points with placebo.¹
Both regimens also beat placebo on the Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP), with reductions of 1.5 and 1.3 points, respectively, versus 0.8 points with placebo. Both active-arm improvements were found to have exceeded the 1.1-unit threshold commonly used to define a clinically important change.¹